Mental Health Diagnostics/ Meditation Apps

Psychedelic Therapeutics Co. Cybin Gets Conditional Listing Approval

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has received conditional listing approval from the NYSE American LLC stock exchange (the “NYSE American”).

Doug Drysdale, Cybin’s CEO, added, “Conditional listing approval on the NYSE American is an important milestone in Cybin’s growth journey. We expect expanded access to investors to further fuel our mission to develop revolutionary psychedelic therapeutics for patients suffering from mental health conditions.”

Any listing remains subject to the approval of the NYSE American and the satisfaction of all applicable regulatory requirements. No assurance can be given that an application will be approved. The Company plans to maintain its current listing on the NEO Exchange. The Company has reserved the ticker CYBN on the NYSE American.

For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to

Related posts

Psychedelic Therapeutics Co. Cybin Closes Overnight Marketed Public Offering

Business Wire

TimelyMD and EVERFI to Transform Student Mental Health & Wellbeing

Business Wire

DiagnaMed Launches, a Generative AI Brain Health Solution